Unique Wealth LLC Takes Position in Edwards Lifesciences Co. (NYSE:EW)

Unique Wealth LLC acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,426 shares of the medical research company's stock, valued at approximately $248,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP increased its holdings in Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after buying an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC raised its position in Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock worth $1,007,520,000 after acquiring an additional 126,194 shares during the period. Fisher Asset Management LLC raised its position in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after acquiring an additional 696,965 shares during the period. Finally, Norges Bank purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $610,895,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares of the company's stock, valued at $4,106,859.33. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. This represents a 1.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,012 shares of company stock valued at $4,224,717 over the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

NYSE:EW traded down $0.21 during trading hours on Friday, reaching $77.56. The stock had a trading volume of 2,633,909 shares, compared to its average volume of 5,219,133. The stock has a market capitalization of $45.50 billion, a PE ratio of 11.13, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a 50 day moving average price of $73.98 and a two-hundred day moving average price of $72.77. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the firm earned $0.66 earnings per share. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on EW. Citigroup restated a "buy" rating and issued a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.